

Characterisation of Chikungunya Virus Neutralising Monoclonal Antibodies expressed in Tobacco Plants

Catherine M. Moore, Mathew J. Paul, Elizabeth Pinneh, Balamurugan Shanmugaraj, James Ashall, Sathishkumar Ramalingam, Roger Hewson, Michael S. Diamond, Julie M. Fox, Julian K-C. Ma



PII: S0168-1656(25)00161-0

DOI: <https://doi.org/10.1016/j.jbiotec.2025.06.014>

Reference: BIOTEC9621

To appear in: *Journal of Biotechnology*

Received date: 28 March 2025

Revised date: 16 June 2025

Accepted date: 29 June 2025

Please cite this article as: Catherine M. Moore, Mathew J. Paul, Elizabeth Pinneh, Balamurugan Shanmugaraj, James Ashall, Sathishkumar Ramalingam, Roger Hewson, Michael S. Diamond, Julie M. Fox and Julian K-C. Ma, Characterisation of Chikungunya Virus Neutralising Monoclonal Antibodies expressed in Tobacco Plants, *Journal of Biotechnology*, (2025) doi:<https://doi.org/10.1016/j.jbiotec.2025.06.014>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Characterisation of Chikungunya Virus Neutralising Monoclonal Antibodies expressed in Tobacco Plants**

*Catherine M. Moore<sup>1,6\*</sup>, Mathew J. Paul<sup>1</sup>, Elizabeth Pinneh<sup>1</sup>, Balamurugan Shanmugaraj<sup>1</sup>, James Ashall<sup>1</sup>, Sathishkumar Ramalingam<sup>2</sup>, Roger Hewson<sup>3</sup>, Michael S. Diamond<sup>4</sup>, Julie M. Fox<sup>5</sup>, Julian K-C. Ma<sup>1\*</sup>.*

\*Corresponding authors

Cathy Moore - [c.moore@westminster.ac.uk](mailto:c.moore@westminster.ac.uk)

Julian Ma – [jma@sgul.ac.uk](mailto:jma@sgul.ac.uk)

<sup>1</sup>Hotung Molecular Immunology Unit, Institute for Infection & Immunity, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK

<sup>2</sup>Department of Biotechnology, Bharathiar University, Coimbatore 641 046

Tamil Nadu, India

<sup>3</sup>London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK;

WHO—Collaborating Centre Virus Reference & Research (Special Pathogens), Salisbury SP4 0JG, UK

UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK

<sup>4</sup>Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA

<sup>5</sup> Emerging Virus Immunity Unit, Laboratory of Viral Diseases, National Institute Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

<sup>6</sup>Current affiliation – School of Life Sciences, University of Westminster, 115 New Cavendish St, London W1W 6UW, UK

Word Count: 3,393. (Abstract: 179)

Authors' contributions: JM designed the study, obtained funding and oversaw the research. RH and MD provided essential reagents and sequences. CM, MP, EP, BS, JA, JF performed the studies and generated the data. JM, CM, MP, SR, RH, MD and JF analysed the data. CM, MP, MD, JF and JM drafted the manuscript. All authors reviewed the draft manuscript and approved the final version.

**ABSTRACT**

Chikungunya virus (CHIKV) causes a debilitating musculoskeletal disease, characterised by flu-like symptoms, rash, and severe joint pain, which can last for months, even after the resolution of infection. Although the first CHIKV vaccine was approved in the USA in 2023 for use in adults, there is currently no specific antiviral therapy for infection. While neutralising antibody-based prophylactic and therapeutic agents have been considered, affordability and accessibility are major barriers to global regions where Chikungunya disease is epidemic. Here, we expressed five anti-CHIKV neutralising IgG monoclonal antibodies (mAbs) in *N. benthamiana* plants to investigate the potential use of this manufacturing platform. Plants produced IgG mAbs that compared favourably to mammalian cell-expressed antibodies, including for binding kinetics to CHIKV antigens and neutralisation activity. The yields of mAbs from plants were variable, as three of the antibodies' yields would need further expression optimisation to warrant future development. The successful expression of these antibodies in *N. benthamiana* plants supports the growing pipeline of Global Health product targets that could be developed using a highly transferable, low-cost, low-tech plant production platform in resource-poor countries.

Keywords: monoclonal antibodies, plants, molecular pharming, immunotherapy, Chikungunya

## Introduction

Chikungunya virus (CHIKV), an alphavirus first identified in Tanzania in 1952, has spread to all six World Health Organisation (WHO)-defined regions, with new areas at risk of future outbreaks, including Europe and the USA (1). While disease caused by CHIKV is not typically associated with mortality, the joint pain and musculoskeletal symptoms are debilitating in the acute phase and can progress to chronic disease lasting for months in up to 40% of cases (2). The first vaccine for Chikungunya virus (IXCHIQ®) was licensed only recently in November 2023 in the United States, and the European Medicines Agency in May 2024 (3). There is no specific antiviral treatment for CHIKV infection, and current approaches are focused on pain management and control of joint inflammation with use of short-term analgesics and non-steroidal anti-inflammatory drugs (4). The mechanism and risk factors for transition to chronic Chikungunya arthritis in some patients is uncertain.

One approach that has been considered for CHIKV infection and disease is immunotherapy with neutralising monoclonal antibodies (mAbs). Anti-Chikungunya mAbs have already shown promise for protection against disease in both mouse and non-human primate models (5, 6), and a lipid-encapsulated mRNA encoding a neutralizing anti-CHIKV human mAb has completed phase I clinical trials (7). Moreover, several of these mAbs were protective when administered either 24 hours before or up to 60 hours post-infection even though the window of viremia is only 3 to 4 days. As post-exposure therapy, mAbs were effective in limiting viral spread to joints and muscles and reduced tissue inflammation in mice (8, 9) and rhesus macaques (6, 10). In humans, the acute viraemic phase for CHIKV-infection is slightly longer, lasting 4–12 days post-symptom onset, which potentially offers a longer treatment window

(11). Chronic musculoskeletal tissue pathology is believed to be caused by persistent CHIKV infection or the presence of viral RNA. Prophylaxis with mAbs was shown to effectively prevent the establishment of CHIKV persistence (12).

mAbs are widely used in medicine, including against cancer and chronic autoimmune disease, but are less commonly used for infectious disease applications and have almost no impact on diseases in low to middle income countries (LMICs). Palivizumab was the first commercially developed and approved antiviral mAb biologic for the prevention of respiratory syncytial virus (RSV) (13) and led the way for further development of anti-RSV mAbs (14). Therapeutic mAbs against Ebola virus and SARS-CoV-2 have also subsequently been approved (15, 16). Nonetheless, mAbs produced in mammalian cell cultures remain prohibitively expensive and only accessible by high income populations (17). The issue of affordability is compounded by the need for cocktails of mAbs (e.g., 3 mAbs in Inmazeb against Ebola virus) to circumvent viral escape (18), an accessibility issue highlighted by WHO in their recommendations for Ebola treatment (19). While infectious diseases remain predominantly associated with LMICs, deployment of mAb-based biologicals will remain an unrealistic goal unless new approaches are established to make them affordable and accessible.

Here, we explored the feasibility of producing CHIKV neutralising mAbs in plants. Plant biotechnology offers a scalable and potentially more cost-effective approach, in which plants are used as bioreactors to produce recombinant mAbs (20, 21). A key attraction is that a substantially lower initial investment is required to establish the manufacturing platform, compared with traditional mammalian cell

culture production platforms (22, 23). This offers LMICs the opportunity to establish their own production capacity for diseases relevant to their own region (24).

Using neutralizing mAbs that had previously been produced by mammalian cell culture, we codon-optimized mAb light and heavy chain gene sequences and expressed them in *Nicotiana benthamiana* (25). Purified proteins were characterised and compared to the same antibody produced by mammalian cells, in terms of antigen binding and breadth of viral neutralisation. Our results show that plants can be used reliably as a manufacturing platform for producing anti-CHIKV mAbs. Their use could help eventually offset the prohibitive expense of mammalian cell-derived mAb therapies, allowing the most affected regions to take ownership of treatment development programs.

### **Methods and Materials**

Five previously reported CHIKV neutralising IgG mAbs were studied. mAbs CHK-152, CHK-166 and CHK-263 were derived from a screen of 230 mouse mAbs and selected for their ability to inhibit infection of all three CHIKV genotypes and confer protection in a mouse challenge model (6). Two additional human mAbs against CHIKV, 5F10 and 8B10 were also selected. These mAbs were isolated from CD40-activated B cells of infected patients (26) and also protect mice from CHIKV infection (27).

### **Cloning**

Heavy and light chain coding region sequences were obtained (6, 26), and the variable region DNA sequences were plant codon-optimised and synthesised by GeneArt (ThermoFisher). These heavy and light chain variable region sequences were inserted

into the pTRAk.6 vector using an in-house cloning system (28). Briefly, heavy and light chain variable regions were digested with *NcoI/XbaI* and ligated into pWhite and pBlue entry vectors respectively, upstream of the human  $\gamma 1$  and  $\kappa$  chain constant regions already present in these vectors. This resulted in genes for mouse/human chimaeric antibodies in the case of mAbs CHK-152, CHK-166 and CHK-263. After confirmatory DNA sequencing, heavy and light chains were then both inserted, using Golden Gate cloning (*BsaI/BsmBI*), into the pTRAk.6 *Agrobacterium* binary vector. The pTRAk.6 vectors were used to transform *Agrobacterium tumefaciens* strain GV3101:pM90RK by electroporation.

### ***N. benthamiana* infiltration**

Seeds from a *N. benthamiana* line that was gene edited to remove  $\beta 1-2$  xylosylation and  $\alpha 1-3$  fucosylation (29) were germinated and grown in a greenhouse with a 16/8-hour day/night cycle at 24-28°C for 4 to 6 weeks. Leaf infiltrations were carried out as described (30). Briefly, recombinant *Agrobacterium tumefaciens* were grown until an optical density (O.D.)<sub>600nm</sub> of 2 to 4 was achieved. The bacteria were pelleted and resuspended in infiltration solution (10 mM MgCl<sub>2</sub>, 10 mM MES) at an O.D.<sub>600nm</sub> of 0.1 and incubated at room temperature for a minimum of 30 mins with 200  $\mu$ M acetosyringone. Plants were infiltrated manually using a syringe or by vacuum infiltration for larger scale expression. Plant leaves were harvested five days post infiltration for extraction of recombinant antibodies.

### ***Gel electrophoresis***

SDS-PAGE was performed following manufacturer's instructions (Invitrogen, NuPAGE), using 4-12% Bis-Tris SDS-PAGE gels run in MOPS buffer, which were stained with InstantBlue® Coomassie Protein Stain (Abcam).

### ***Antibody purification***

Antibody was purified as described previously (30). Briefly, infiltrated plants were homogenised in a blender and filtered through miracloth (Sigma) to remove plant debris. The filtrate was centrifuged for 40 mins at 16,000 g, before passing the supernatant through a 0.22 µm filter. Antibodies were purified using affinity chromatography by passing the filtrates through a Protein A column (Protein A agarose, Sigma). Eluates were dialysed overnight at 4°C and concentrated by buffer exchange in 100 kDa Centricon® centrifugal filters. Antibodies were filter-sterilised and quantified using Nanodrop™ 2000 spectrophotometer (Thermofisher), before storing at 4°C, or aliquoting and storing at -80°C.

### ***ELISAs***

ELISAs were performed as previously described to confirm mAb binding activity (31). Briefly, ELISA plates were coated with 1 µg/mL of recombinant E1 or E2 CHIKV antigens (The Native Antigen Co.) and blocked with PBS + 5% skimmed milk powder. Anti-CHIKV antibody samples (at an estimated concentration of 2 µg/mL) were added in duplicate wells with a 3-fold dilution series. After incubation, anti-CHIKV antibodies were detected with anti-human IgG1 heavy chain antiserum conjugated with HRP (The Binding Site, cat. #AP015), diluted in PBS + 5% skimmed milk powder. Developing solution (3,3 5,5-Tetramethylbenzidine (TMB) Liquid Substrate, Sigma) was added and briefly incubated until colour development was complete before stopping with 2N

H<sub>2</sub>SO<sub>4</sub>. Plates were read on a Tecan Infinite F200 Pro. Data were analysed and concentrations calculated with Graphpad Prism 9. A minimum of three biological repeats was performed for each assay.

### ***Binding kinetics***

Surface plasmon resonance (SPR) was used to calculate binding kinetics of the antibodies to CHIKV antigens, using a BIAcore™ X-100 instrument (GE healthcare, Chalfont St. Giles, UK) (32). All proteins were diluted/resuspended in HBS-EP+ buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.05% surfactant P-20) at 25°C. Protein A (Sigma, cat. #P6031) was immobilised onto a CM5 chip with standard amine coupling, to 5,000 response units. Antibodies CHK-152 and CHK-263 were individually captured onto a protein A-coated sensor chip and recombinant CHIKV-E2 protein was injected over the antibody surface at a range of concentrations (0.2-0.8 µM). Sensorgrams were analysed with a 1:1 binding model to fit the binding behaviour, followed by 1 h of dissociation time and a regeneration step with 10 mM glycine-HCl (pH 1.5). All referenced and blanked sensograms were fitted to Langmuir model of binding (1:1), using BIAcore™ Evaluation software.

For CD16 and CD64 binding kinetics, CHIKV mAbs were captured by Protein A on CM5 chips (as above). Fc receptors (Recombinant Human Fc gamma RIIIA/CD16a Protein and Recombinant Human Fc gamma RI/CD64 Protein, Bio-technie) were injected over the antibody surface at a range of concentrations (0.2-0.8 µM). Kinetic parameters were determined using a 1:1 binding model to fit the binding behaviour.

### ***Neutralisation assays***

Serial dilutions of antibodies were incubated with 100 focus forming units (FFU) of CHIKV (strain LR2006\_OPY1) for 1 h at 37°C then added to Vero cell monolayers for 1.5 h at 37°C. The cells were then overlaid with 1% methylcellulose in minimum essential medium supplemented with 2% heat inactivated FBS, HEPES, and penicillin and streptomycin. After 18 h, the cells were fixed with 1% paraformaldehyde in PBS and then permeabilized. The cells were then stained with CHK-11 mAb (6) overnight followed by an anti-mouse IgG conjugated to peroxidase (SeraCare) for 2 h at room temperature. Foci were developed with TrueBlue Peroxidase Substrate (KPL) and counted on a Biospot plate reader (Cellular Technology, Inc.). IC<sub>50</sub> values were determined by non-linear regression with the top and bottom constrained to 100 and 0, respectively. The focus reduction neutralization tests were performed under BSL-3 conditions.

## Results

### *mAb expression*

The plant codon-optimised genes for the five anti-CHIKV mAbs resulted in different expression levels. Pre-purification yields were 64.7 mg/Kg (fresh leaf mass) for the chimaeric CHK-152, 49.6 mg/Kg for chimaeric CHK-263, 27 mg/Kg for chimaeric CHK-166 antibodies, and 35 mg/Kg and 15 mg/Kg for the human 8B10 and 5F10 mAbs respectively.

**Figure 1** shows a Coomassie stained SDS-PAGE gel of the anti-CHIKV mAbs expressed and purified from *N. benthamiana*. The positive control is a commercial purified human IgG1k mAb. Major bands around 150 kDa were detected under non-reducing (N) conditions, the expected size for fully assembled IgG mAbs. Some

evidence for degradation was observed for CHK-152, CHK-263, and 8B10. Under reducing (R) conditions, individual heavy and light chains are detected at the expected sizes of approximately 55 kDa and 27 kDa.

### ***Antigen binding***

All five mAbs demonstrated specific binding to CHIKV antigens (**Figure 2A**). There was no binding to LDH, a non-specific antigen (data not shown). CHK-166 recognised recombinant E1 protein, whereas CHK-152, CHK-263, 5F10 and 8B10 showed binding to recombinant E2 protein.

Detection of antigen binding by CHK-152 and CHK-263 appeared less potent than for 5F10 and 8B10, so the binding kinetics for E2 antigen were explored in more detail by surface plasmon resonance (**Figure 2B**). Binding to E2 was confirmed and the affinities ( $K_D$ ) for the plant-expressed CHK-152 and CHK-263 antibodies were calculated as  $1.18 \times 10^{-10}$  M, and  $4.40 \times 10^{-11}$  M respectively.

### ***Binding to $Fc\gamma$ receptors***

The binding kinetics to the high affinity  $Fc\gamma RI$  (CD64) receptor and a low affinity  $Fc\gamma RIIIa$  (CD16) receptor were measured for all five mAbs by surface plasmon resonance (**Figure 3**). The results were consistent for all antibodies, with a  $K_D$  range of  $4.63$ - $5.31 \times 10^{-10}$  for CD64 and  $2.64$ - $3.45 \times 10^{-8}$  for CD16, with the latter results being consistent for non-fucosylated IgG mAbs (31).

### ***Neutralisation assays***

To measure neutralisation of Chikungunya virus, we performed focus reduction neutralization tests (FRNT) (**Figure 4**). For mAbs CHK-152, CHK-166 and CHK-263, a direct comparison between antibodies produced in plants or from hybridomas was made and the FRNT-derived IC<sub>50</sub> values were comparable (**Figure 4A**). The IC<sub>50</sub> values for plant-produced 8B10 and 5F10 were 32 and 36 ng/ml respectively (**Figure 4B**), consistent with published values of these antibodies (26).

## Discussion

Since its initial discovery more than 70 years ago, CHIKV has periodically caused epidemics in Africa and Asia. In 2005-2006, a major outbreak in the Indian ocean region later led to imported cases across Asia, Australia, North America and Europe. In 2007, a local outbreak of Chikungunya disease appeared for the first time in Southern Europe, and there have since been further local outbreaks in France. In 2013, CHIKV spread to the Caribbean and South America, and the virus currently circulates across the sub-tropical regions of America, Africa and Asia (33). CHIKV is primarily transmitted to people by infected mosquitoes, and the risk of global spread is increasing due to importation through infected travellers, presence of competent vectors in many countries (particularly around the Mediterranean coast), global warming, and population susceptibility (34). Thus, CHIKV is an emerging global health threat. In 2024, as of 30<sup>th</sup> September, approximately 460,000 chikungunya virus disease cases and 170 CHIKV associated deaths were reported worldwide from 23 countries (ECDC <https://www.ecdc.europa.eu/en/chikungunya-monthly>).

Current options to manage Chikungunya infection outbreaks are limited. The first anti-CHIKV vaccine (IXCHIQ®) was approved in November 2023, but it is currently only licensed for use in adults in Europe and the USA. It is a live-attenuated vaccine, and

severe chikungunya-like adverse reactions were observed in some recipients. As a consequence, a post-marketing study was requested to assess this serious potential risk (35).

Experience with other vaccines for tropical diseases suggests that affordability will be a key consideration as to whether the vaccine is widely used in the low- and middle-income country settings where it is most needed (36). IXCHIQ® also does not provide a protection strategy for children. In addition, vaccine hesitancy is a growing concern worldwide, so further clinical options are urgently needed (37). There is no specific antiviral drug treatment for CHIKV infection.

Whilst mammalian cell-derived mAbs could be used in multiple ways to manage Chikungunya infection, they are expensive and currently even less accessible to LMICs than vaccines (38). An additional complicating factor is that a single mAb may not provide sufficient protection against all circulating viral strains, and viral escape may also develop. For these reasons, mAb combinations or cocktails are generally considered advisable (6), but this potentially multiplies the cost of a drug product.

Plant manufacturing platforms for protein biologics are emerging as an alternative to conventional cell culture systems, particularly as manufacturing facilities are potentially much more affordable for resource poor regions (24). Manufacturing in plants has been used for the production of Ebola mAbs (39) and a COVID vaccine (40) in North America, providing proof-of-concept and demonstrating a potential regulatory path forward. As a consequence, the recent establishment of plant manufacturing facilities for biologics in resource poor regions, such as Baiya Phytopharma in Thailand ([baiyaphytopharm.com](http://baiyaphytopharm.com)), Cape Biologix in South Africa

(capebiologix.com) and the Bio-Manguinhos/Fiocruz Centre in Ceara (ceara.fiocruz.br/portal/index.php/inovacao-e-producao/bio-manguinhos/) heralds the beginning of a potentially important shift in biologics manufacture, that could allow LMICs to determine and prioritise their own healthcare needs.

Several promising Chikungunya neutralising mAbs have been reported (41), including in plants. Hurtado et al., previously reported the expression of a CHIKV neutralising mAb in plants and demonstrated *in vitro* and *in vivo* efficacy (42). Esqueda et al., also reported a bispecific antibody against dengue and chikungunya virus in plants, using the CHK-152 mAb sequence (43). In our study, anticipating the possible need for a mAb cocktail drug product, we expressed five different anti-CHIKV neutralising mAbs by transient expression in *N. benthamiana*, and in three cases demonstrated a functional equivalence of virus neutralisation with the same antibody sequences purified from hybridoma supernatant.

The antibodies selected here were based on their epitope specificities, potent neutralisation activity, and protective activity in animal models. Our data confirm that the antigen specificity of the plant-produced version of these mAbs was preserved. mAbs 8B10 and 5F10 bind distinct epitopes on E2 (44). mAb 8B10 binds radially from the viral surface and blocks receptor binding on the E2 glycoprotein. mAb 5F10 binds the tip of the E2 B domain and fixes the B domain rigidly to the surface of the virus, blocking exposure of the fusion loop on glycoprotein E1 and therefore preventing the virus from becoming fusogenic (44). mAbs CHK-152 and CHK-263 were mapped to distinct epitopes on the E2 protein, and CHK-166 binds an epitope on the E1 protein (6). Analysis of amino acid changes in escape mutants showed that neutralization

escape residues for CHK-263 localised to the B domain of E2 (6). The residues that modulated CHK-152 neutralization mapped to the A domain of E2. In contrast, CHK-166 recognized amino acids on DII of E1, adjacent to the fusion loop. Furthermore, low resolution cryo-electron microscopy structures of CHIKV VLPs in complex with Fab fragments revealed that CHK-152 spans E2 domain A and domain B as well as the  $\beta$ -ribbon connector connecting the two domains within one E2 molecule (45).

*In vivo*, mAbs 8B10 and 5F10 were previously shown to protect mice from CHIKV infection (27). mAbs CHK-152, CHK-166 and CHK-263 were also protective in a pre-exposure mouse model. Furthermore, in a post-exposure therapeutic mouse model, administration of CHK-263+CHK-152 or CHK-166+CHK-152 at 24 h post infection completely prevented mortality and emergence of resistance in all animals (6). The combination mAb therapy of CHK-152 and CHK-166 has also been tested in a nonhuman primate model of CHIKV infection. Rhesus macaques treated with these antibodies had reduced viral spread and infection, with neutralized reservoirs of infectious virus. No escape viruses were detected (46). The results from animal studies are therefore supportive that selected pairs of highly neutralizing MAbs may be a promising treatment option for CHIKV in humans.

We found that the each anti-CHIKV mAb was expressed with different yields in plants. This is not unexpected, even though the only difference in sequence lies in the variable regions of the antibodies (47). The best expressing antibodies in plants were CHK-152 and CHK-263, which fortuitously have the strongest neutralizing activities. These two mAbs are clear candidates for development, whereas further yield optimisation is

likely needed before the other three mAbs can be advanced, as their initial yields were below the lower limit for manufacturing feasibility (20). With regards to downstream purification, we used Protein A affinity chromatography successfully, which is a key step in mAb manufacture. Previous work has identified a path for further upstream and downstream processing, to reach the product quality required for use in human clinical trials (48, 49).

Functionally, the plant produced mAbs performed as expected. Antigen binding was confirmed by ELISA and in the case of mAbs CHK-152 and CHK-263 binding kinetics derived from SPR experiments confirmed high binding affinity in the sub-nanomolar range (6).

N-linked glycosylation in plants is well understood and has been the subject of much investigation (50). IgG mAbs produced in plants have been reported to have much better homogeneity on N-linked glycans (49). Furthermore, the glycoengineering strategy used in this study, which is commonly used for plant expression, eliminates N-linked glycan residues ( $\beta$ 1,2-linked xylose, core  $\alpha$ 1,3-linked fucose) that are commonly found in plants, but not humans. Thus, the resulting IgG mAb only displays N-linked glycans that are also found in normal human IgG (29). De-fucosylation of IgG antibodies leads to an improvement in binding affinity to the low affinity CD16a Fc receptor, that is found on natural killer cells and linked with ADCC (51). We confirmed the binding affinity of the plant CHIKV mAbs to high and low affinity Fc $\gamma$  receptors CD64 and CD16, which was consistent with previously published results (32). This is pertinent because previously it was shown that the effector functions of at least CHK-152 contribute to protection *in vivo* (6). When CHK-152 and CHK-166 were

administered as post-exposure therapy in mice, the Fc effector functions of both mAbs promoted virus clearance from infected cells and reduced joint swelling (9).

Finally, virus neutralisation activity was tested. CHK-152, CHK-166 and CHK-263 plant antibodies all performed equivalently compared to their mammalian cell-produced counterparts. For plant-produced 8B10 and 5F10, IC50 values were consistent with previously reported historical data from CHO derived mAbs (6, 26).

Overall, this study demonstrates that murine/human chimeric and human anti-CHIKV antibodies can be efficiently expressed in tobacco plants without loss of function. This raises the prospect of developing a low-cost, low-tech production platform for a mAb cocktail to control chikungunya disease in low- to middle-income countries.

### **Funding:**

We gratefully acknowledge support from the Hotung Charitable Foundation (JM) for this work. The research was also supported by EU Horizon 2020 (Grant Agreement No. 774078, Pharma-Factory and Grant Agreement No. 760331, Newcotiana) (JM, CM, EP, MP), thematic partnership funding No.332 from the UK-India Education and Research Initiative (JM, MP, BS, SR), and by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH (JF).

### **Conflict Of Interest Statement**

M.S.D. is a consultant or advisor for Inbios, Vir Biotechnology, IntegerBio, Moderna, Merck, and GlaxoSmithKline. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and IntegerBio. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report.

### **Sequence information:**

N/A

### **Ethical Approval:**

No ethical approval was required.

### **Abbreviations**

ELISA Enzyme-Linked Immunosorbent Assay

PBS Phosphate-buffered Saline

O.D. Optical density

ADCC Antibody-Dependent Cellular Cytotoxicity

SPR Surface Plasmon Resonance

mAb Monoclonal Antibody

RU Response Units

RLU Relative Light Units

HRP Horse Radish Peroxidase


SDS PAGE Sodium Dodecyl Sulphate Poly-Acrylamide Gel Electrophoresis

IgG Immunoglobulin G

Journal Pre-proof


## Figure captions:

Figure 1 Moore et al., 2024



**Figure 1: Purified anti-CHIKV antibodies produced in *N. benthamiana*.** Purified plant-produced CHK-152, CHK-166, CHK-263, 5F10, 8B10 mAbs and purified human IgG1 kappa (Sigma) were electrophoresed under non-reducing (NR) and reducing (R) conditions on 4-12% SDS-PAGE gels. Molecular weight standards (Precision Plus Protein™ All Blue Pre-stained Protein Standards) are indicated. (The marker and two lanes for 5F10 were from the same gel, but intervening samples have been removed for the sake of clarity.). Representative gel images are shown from 3 replicate experiments.

Figure 2 Moore et al., 2024



**Figure 2: Antigen specific binding of purified anti-CHIKV antibodies.** (A) Antigen binding ELISAs. Recombinant antigens E1 and E2 were used to coat the ELISA plates. Anti-CHIKV mAbs were added in duplicate wells at a starting concentration of ~220 ng/mL for E1 ELISAs and ~70 ng/mL for E2 ELISAs, with a 3-fold dilution series. Bound antibodies were detected using HRP-conjugated goat anti-human IgG Fc domain antibody. Data shown as absorbance for mAbs at 450 nm (mean of replicate samples). (B) Surface plasmon resonance for CHK-152 and CHK-263 mAbs binding to recombinant CHIKV E2. Concentrations were 0.8  $\mu$ M (Purple), 0.4  $\mu$ M (Blue), and 0.2  $\mu$ M (red). Association ( $k_a$ ) and dissociation ( $k_d$ ) constants were calculated using the Langmuir 1:1 binding model with BIAcore evaluation software,  $K_D = k_a/k_d$ . Data shown is representative of 3 independent experiments.





Figure 3 Moore et al., 2024

**Figure 3. Surface plasmon resonance measuring binding kinetics of anti-CHIKV mAbs to CD16 and CD64.** Protein A-coated CM5 surface was used to bind CHIKV mAb, and the soluble Fc receptor was added in the fluid phase. **(A)** Binding to CD16a (Fc $\gamma$ RIIIa). Concentrations added were 400 nM (red), 100 nM (purple), 50 nM (green), and 12.5 nM (blue). **(B)** Binding to CD64 (Fc $\gamma$ RI). Concentrations added were 270 nM (red), 90 nM (purple), 30 nM (green), and 10 nM (blue). **(C)** Kinetic parameters from 1:1 Langmuir curve fitting. Affinities ( $K_D$ ) from surface plasmon resonance were estimated using the Langmuir model of binding (1:1), with BIAcore™ Evaluation software. The results are representative of three independent experiments.

Figure 4 Moore et al., 2024



**Figure 4: Neutralization of CHIKV by mAbs.** Focus reduction neutralization tests (FRNT) were performed by incubating indicated mAbs with  $10^2$  focus-forming units of CHIKV (strain LR2006\_OPY1) before adding to Vero cells. The cells were permeabilised and stained with mAb CHK-11. Foci were counted on a Biospot plate reader. IC<sub>50</sub> values are shown. **(A)** mAbs CHK-152, CHK-166 and CHK-263 produced in plants (P) were compared with those produced in hybridomas. A human and mouse isotype IgG was included as a negative control. **(B)** mAbs 8B10 and 5F10 were produced in plants (P). A human isotype IgG was included as a negative control. Graphs show the mean  $\pm$  SD for two independent experiments performed in duplicate. IC<sub>50</sub> values were determined with non-linear regression constraining the top and bottom to 100 and 0, respectively.

## References

1. Rowland-Jones SL. Chikungunya: out of the tropical forests and heading our way. *Trans R Soc Trop Med Hyg.* 2016;110(2):85-6.
2. Amaral JK, Bingham CO, 3rd, Schoen RT. Successful Methotrexate Treatment of Chronic Chikungunya Arthritis. *J Clin Rheumatol.* 2020;26(3):119-24.

3. Maure C, Khazhidinov K, Kang H, Auzenberg M, Moyersoen P, Abbas K, et al. Chikungunya vaccine development, challenges, and pathway toward public health impact. *Vaccine*. 2024;42(26):126483.
4. Kennedy Amaral Pereira J, Schoen RT. Management of chikungunya arthritis. *Clin Rheumatol*. 2017;36(10):2179-86.
5. Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, et al. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. *PLoS Negl Trop Dis*. 2013;7(9):e2423.
6. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. *PLoS Pathog*. 2013;9(4):e1003312.
7. August A, Attarwala HZ, Himansu S, Kalidindi S, Lu S, Pajon R, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. *Nat Med*. 2021;27(12):2224-33.
8. Jin J, Liss NM, Chen DH, Liao M, Fox JM, Shimak RM, et al. Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. *Cell Rep*. 2015;13(11):2553-64.
9. Fox JM, Roy V, Gunn BM, Huang L, Edeling MA, Mack M, et al. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-Fcγ3 interaction on monocytes. *Sci Immunol*. 2019;4(32).
10. Broeckel R, Fox JM, Haese N, Kreklywich CN, Sukulpovi-Petty S, Legasse A, et al. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. *PLoS Negl Trop Dis*. 2017;11(6):e0005637.
11. Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan R, Silpapojakul K. Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? *Transfusion*. 2013;53(10 Pt 2):2567-74.
12. Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, et al. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. *J Virol*. 2013;87(24):13878-88.
13. Null D, Bimle C, Weisman L, Johnson K, Steichen J, Singh S, et al. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. *Pediatrics*. 1998;102(3):531-7.
14. Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. *New Engl J Med*. 2023;389(26):2425-35.
15. Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. *Lancet Infect Dis*. 2022;22(11):e311-e26.
16. Rijal P, Donnellan FR. A review of broadly protective monoclonal antibodies to treat Ebola virus disease. *Curr Opin Virol*. 2023;61.
17. Gieber L, Muturi-Kioi V, Malhotra S, Sitlani A. Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond. *Pharmaceut Med*. 2023;37(3):203-14.
18. Rayaprolu V, Fulton BO, Rafique A, Arturo E, Williams D, Hariharan C, et al. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. *Cell Host Microbe*. 2023;31(2):260-72 e7.

19. WHO. WHO makes new recommendations for Ebola treatments, calls for improved access 2022 [Available from: <https://www.who.int/news/item/19-08-2022-who-makes-new-recommendations-for-ebola-treatments-----calls-for-improved-access>].
20. Moore CM, Grandits M, Grünwald-Gruber C, Altmann F, Kotouckova M, Teh AYH, et al. Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants. *Retrovirology*. 2021;18(1).
21. Moore CM, Ljungars A, Paul MJ, Dahl CH, Ahmadi S, Adams AC, et al. Characterisation of two snake toxin-targeting human monoclonal immunoglobulin G antibodies expressed in tobacco plants. *Toxicon*. 2023;232:107225.
22. Stoger E, Fischer R, Moloney M, Ma JK. Plant molecular pharming for the treatment of chronic and infectious diseases. *Annu Rev Plant Biol*. 2014;65:743-68.
23. McNulty MJ, Gleba Y, Tuse D, Hahn-Lobmann S, Giritich A, Nandi S, et al. Techno-economic analysis of a plant-based platform for manufacturing antimicrobial proteins for food safety. *Biotechnol Prog*. 2020;36(1):e2896.
24. Murad S, Fuller S, Menary J, Moore C, Pinneh E, Szeto T, et al. Molecular Pharming for low and middle income countries. *Curr Opin Biotechnol*. 2020;61:53-9.
25. Teh AY, Cavacini L, Hu Y, Kumru OS, Xiong J, Bolick DT, et al. Investigation of a monoclonal antibody against enterotoxigenic *Escherichia coli*, expressed as secretory IgA1 and IgA2 in plants. *Gut Microbes*. 2021;13(1):1-14.
26. Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT, et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. *J Immunol*. 2011;186(5):3258-64.
27. Fric J, Bertin-Maghit S, Wang CI, Nardin A, Warter L. Use of human monoclonal antibodies to treat Chikungunya virus infection. *J Infect Dis*. 2013;207(2):319-22.
28. Pinneh EC, van Dolleweerd CJ, Goritzer K, Drake PMW, Ma JK, Teh AY. Multiple gene expression in plants using MIDAS-P, a versatile type II restriction-based modular expression vector. *Biotechnol Bioeng*. 2022.
29. Jansing J, Sack M, Augustine SM, Fischer R, Bortesi L. CRISPR/Cas9-mediated knockout of six glycosyltransferase genes in *Nicotiana benthamiana* for the production of recombinant proteins lacking beta-1,2-xylose and core alpha-1,3-fucose. *Plant Biotechnol J*. 2019;17(2):350-61.
30. Teh AY, Maresch D, Klein K, Ma JK-C. Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. *Plant Biotechnol J*. 2013.
31. Webster GR, van Dolleweerd C, Guerra T, Stelter S, Hofmann S, Kim MY, et al. A polymeric immunoglobulin-antigen fusion protein strategy for enhancing vaccine immunogenicity. *Plant Biotechnol J*. 2018;16(12):1983-96.
32. Stelter S, Paul MJ, Teh AY, Grandits M, Altmann F, Vanier J, et al. Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. *Plant Biotechnol J*. 2020;18(2):402-14.
33. WHO. Chikungunya Factsheet 2022 [Available from: <https://www.who.int/news-room/fact-sheets/detail/chikungunya>].
34. Watson R. Europe witnesses first local transmission of chikungunya fever in Italy. *BMJ*. 2007;335(7619):532-3.
35. Ly H. Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection. *Virulence*. 2024;15(1):2301573.

36. Guillaume D, Meyer D, Waheed DE, Schlieff M, Muralidharan K, Chou VB, et al. Factors influencing the prioritization of vaccines by policymakers in low- and middle-income countries: a scoping review. *Health Policy Plan.* 2023;38(3):363-76.
37. Nuwarda RF, Ramzan I, Weekes L, Kayser V. Vaccine Hesitancy: Contemporary Issues and Historical Background. *Vaccines (Basel).* 2022;10(10).
38. Eaton EF, Tamhane A, Saag M, Mugavero MJ, Kilgore ML. Cost considerations in the current antiretroviral era. *AIDS.* 2016;30(14):2115-9.
39. Group PIW, Multi-National PIIST, Davey RT, Jr., Dodd L, Proschan MA, Neaton J, et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. *N Engl J Med.* 2016;375(15):1448-56.
40. Hager KJ, Perez Marc G, Gobeil P, Diaz RS, Heizer G, Llapur C, et al. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. *N Engl J Med.* 2022;386(22):2084-96.
41. Chandley P, Lukose, A., Kumar, R., Rohatgi, S. . An overview of anti-Chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelope. *The Microbe.* 2023;1.
42. Hurtado J, Acharya D, Lai H, Sun H, Kallolimath S, Steinkellner H, et al. In vitro and in vivo efficacy of anti-chikungunya virus monoclonal antibodies produced in wild-type and glycoengineered *Nicotiana benthamiana* plants. *Plant Biotechnol J.* 2020;18(1):266-73.
43. Esqueda A, Jugler C, Chen Q. Design and expression of a bispecific antibody against dengue and chikungunya virus in plants. *Methods Enzymol.* 2021;660:223-38.
44. Porta J, Mangala Prasad V, Wang Cl, Akahata W, Ng LF, Rossmann MG. Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. *J Virol.* 2016;90(3):1169-77.
45. Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X, et al. Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. *Elife.* 2013;2:e00435.
46. Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, et al. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. *J Virol.* 2014;88(15):8213-26.
47. Niemer M, Mehofer U, Torres Acosta JA, Verdianz M, Henkel T, Loos A, et al. The human anti-HIV antibodies 2F5, 2G12, and PG9 differ in their susceptibility to proteolytic degradation: down-regulation of endogenous serine and cysteine proteinase activities could improve antibody production in plant-based expression platforms. *Biotechnol J.* 2014;9(4):493-500.
48. Sparrow PA, Irwin JA, Dale PJ, Twyman RM, Ma JK. Pharma-Planta: road testing the developing regulatory guidelines for plant-made pharmaceuticals. *Transgenic Res.* 2007;16(2):147-61.
49. Ma JK, Drossard J, Lewis D, Altmann F, Boyle J, Christou P, et al. Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. *Plant Biotechnol J.* 2015;13:1106-20.
50. Cabanes-Macheteau M, Fitchette-Laine AC, Loutelier-Bourhis C, Lange C, Vine ND, Ma JKC, et al. N-glycosylation of a mouse IgG expressed in transgenic tobacco plants. *Glycobiology.* 1999;9(4):365-72.

51. Coenon L, Villalba M. From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement. *Front Immunol.* 2022;13:913215.

Journal Pre-proof

## Conflict Of Interest Statement

M.S.D. is a consultant or advisor for Inbios, Vir Biotechnology, IntegerBio, Moderna, Merck, and GlaxoSmithKline. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and IntegerBio. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report.

Five anti-chikungunya (CHIKV) neutralizing monoclonal antibodies (mAbs) were successfully expressed in *Nicotiana benthamiana* plants, demonstrating the feasibility of this production method.

The plant-produced IgG mAbs exhibited favourable binding kinetics to the CHIKV E1 and E2 antigens and maintained neutralisation activity comparable to mammalian cell-derived antibodies.

This study supports the use of plant-based platforms as a low-cost, scalable alternative for producing global health products, particularly in resource-limited regions where CHIKV is endemic.